Physician profile
Robert E Lending
NPI 1154389807
$10,732.57
in general payments reported to CMS, 2019-2025
30 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,648 · 2020: $642 · 2021: $320 · 2022: $488 · 2023: $498 · 2024: $547 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334 · Honoraria: $300 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.48 |
| Honoraria | $300.00 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,785.14 | 2019-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $574.54 | 2019-2022 | |
| Chiesi USA, INC. | $322.18 | 2025 | Juxtapid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.15 | 2022-2025 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $208.18 | 2020-2024 | Arexvy, Shingrix |
| Medicure Pharma INC. | $199.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $153.83 | 2019-2025 | |
| Boston Scientific Corporation | $150.00 | 2024 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $148.87 | 2019-2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $140.35 | 2019-2024 | Farxiga |
| Exact Sciences Corporation | $127.14 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $124.82 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Kestra Medical Technology Services, INC. | $121.41 | 2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $88.05 | 2019 | |
| Pfizer INC. | $70.99 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $55.40 | 2019-2022 | |
| Radius Health, INC. | $40.31 | 2020-2023 | Tymlos |
| Novo Nordisk INC | $33.05 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $21.25 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.58 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $18.17 | 2025 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $17.83 | 2022 | |
| Averitas Pharma INC. | $16.06 | 2023 | Qutenza |
| Lilly USA, LLC | $16.02 | 2024 | Mounjaro, Zepbound |
| Amryt Pharma Holdings LTD | $15.10 | 2021 | |
| Biogen, INC. | $12.50 | 2020 | |
| Digestive Care, INC. | $11.83 | 2023 | Pertzye |
| Travere Therapeutics, INC. | $10.66 | 2020-2023 | Cholbam |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lending listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.